De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MaxCyte Beheer

Beheer criteriumcontroles 2/4

De CEO MaxCyte's is Maher Masoud, benoemd in Jan2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 890.37K, bestaande uit 50.5% salaris en 49.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.095% van de aandelen van het bedrijf, ter waarde £ 293.01K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 3.3 jaar.

Belangrijke informatie

Maher Masoud

Algemeen directeur

US$890.4k

Totale compensatie

Percentage CEO-salaris	50.5%
Dienstverband CEO	less than a year
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	1.4yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 09

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

May 30

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Mar 14

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 15

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

May 14

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Apr 27

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Nov 20

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 02

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Nov 17

We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Jul 25

MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain

Feb 22

Analyse CEO-vergoeding

Hoe is Maher Masoud's beloning veranderd ten opzichte van MaxCyte's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$35m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$890k	US$450k	-US$38m
Sep 30 2023	n/a	n/a	-US$37m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$791k	US$413k	-US$24m

Compensatie versus markt: De totale vergoeding ($USD 890.37K ) Maher } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 1.02M ).

Compensatie versus inkomsten: De vergoeding van Maher is gestegen terwijl het bedrijf verliesgevend is.

CEO

Maher Masoud (49 yo)

less than a year

Tenure

US$890,365

Compensatie

Mr. Maher Masoud is President, CEO & Executive Director of MaxCyte, Inc. since January 1, 2024 and served as its Head of Global Business Development and Legal Officer since November 2023 and had been its S...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Maher Masoud	President	less than a year	US$890.37k	0.095% $ 284.0k
Douglas Doerfler	Founder	26.3yrs	US$3.14m	0.32% $ 946.3k
Douglas Swirsky	Chief Financial Officer	1.6yrs	US$1.29m	geen gegevens
Jay Gelfman	Senior Vice President of Operations	less than a year	geen gegevens	geen gegevens
Ronald Holtz	Executive Vice President of Administration	1.6yrs	US$948.33k	geen gegevens
David Sandoval	Senior Vice President	less than a year	geen gegevens	geen gegevens
Thomas Ross	Executive Vice President of Global Sales	10.1yrs	geen gegevens	0.024% $ 71.0k
Jack Horgan	Vice President of Corporate Development	less than a year	geen gegevens	geen gegevens
Jill Mayer	Senior Vice President of Human Resources	less than a year	geen gegevens	geen gegevens
J. Thompson	Consultant	3yrs	US$264.50k	geen gegevens
James Brady	Senior VP of Technical Applications & Customer Support	3.2yrs	geen gegevens	geen gegevens
Ali Soleymannezhad	Executive VP of Bioprocessing	1.2yrs	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MXCT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Maher Masoud	President	less than a year	US$890.37k	0.095% $ 284.0k
William Brooke	Independent Non-Executive Director	20.6yrs	US$177.24k	0.048% $ 142.9k
Arthur Mandell	Independent Non-Executive Director	18.4yrs	US$170.49k	0.36% $ 1.1m
Patrick Balthrop	Independent Non-Executive Director	1.9yrs	US$155.49k	0% $ 0
Richard Douglas	Independent Non-Executive Chairman of the Board	6.7yrs	US$190.49k	0.095% $ 284.0k
Stanley Erck	Independent Non-Executive Director	19.6yrs	US$162.24k	0.24% $ 703.6k
John Johnston	Independent Non-Executive Director	8.8yrs	US$160.49k	0.11% $ 342.5k
Yasir Al-Wakeel	Independent Non-Executive Director	3.3yrs	US$238.53k	0% $ 0
Rekha Hemrajani	Independent Non-Executive Director	3.3yrs	US$243.03k	0% $ 0
Marcela Maus	Member of Scientific Advisory Board	1.6yrs	geen gegevens	geen gegevens
Cenk Sumen	Member of Scientific Advisory Board	less than a year	US$897.25k	0% $ 0
Oliver Rando	Member of Scientific Advisory Board	1.6yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MXCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

MaxCyte Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Independent Non-Executive Director notifies of intention to sell stock

Insider notifies of intention to sell stock

President recently bought UK£384k worth of stock

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

Founder exercised options and sold UK£100k worth of stock

Recent updates

Independent Non-Executive Director notifies of intention to sell stock

MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024

MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index

Insider notifies of intention to sell stock

President recently bought UK£384k worth of stock

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

New major risk - Revenue and earnings growth

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

Founder exercised options and sold UK£100k worth of stock

Independent Non-Executive Director notifies of intention to sell stock

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Consensus revenue estimates fall by 22%

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock

Founder exercised options and sold UK£173k worth of stock

Consensus revenue estimates fall by 11%

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

High number of new directors

Key Executive recently bought UK£280k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

Founder exercised options and sold UK£139k worth of stock

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Founder exercised options and sold UK£127k worth of stock

Insider exercised options and sold UK£113k worth of stock

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Consensus forecasts updated

MaxCyte, Inc. Provides Revenue Guidance for 2022

Insider exercised options and sold UK£154k worth of stock

Insider exercised options and sold UK£147k worth of stock

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Maxcyte, Inc. Revenue Guidance for 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index